112 related articles for article (PubMed ID: 1297640)
1. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction.
Yew WW; Lee J; Wong PC; Kwan SY
Int J Clin Pharmacol Res; 1992; 12(4):173-8. PubMed ID: 1297640
[TBL] [Abstract][Full Text] [Related]
2. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.
Tuber Lung Dis; 1992 Feb; 73(1):59-67. PubMed ID: 1326349
[TBL] [Abstract][Full Text] [Related]
3. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction.
Yew WW; Chau CH; Wong PC; Lee J; Wong CF; Cheung SW; Chan CY; Cheng AF
Drugs Exp Clin Res; 1995; 21(2):79-83. PubMed ID: 7555613
[TBL] [Abstract][Full Text] [Related]
4. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report.
Saigal S; Agarwal SR; Nandeesh HP; Sarin SK
J Gastroenterol Hepatol; 2001 Sep; 16(9):1028-32. PubMed ID: 11595068
[TBL] [Abstract][Full Text] [Related]
5. Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens.
Shamaei M; Mirsaeidi M; Baghaei P; Mosaei H; Marjani M; Tabarsi P
Am J Ther; 2017; 24(2):e144-e149. PubMed ID: 26057141
[TBL] [Abstract][Full Text] [Related]
6. [Clinical aspects and outcome of recurrent pulmonary tuberculosis].
Krasnov VA; Potashova VA; Zyrianova TV; Naryshkina SL
Probl Tuberk; 1993; (5):14-6. PubMed ID: 8295875
[TBL] [Abstract][Full Text] [Related]
7. Tuberculosis therapy.
Lefrock JL; Smith BR
Am Fam Physician; 1983 Mar; 27(3):261-4. PubMed ID: 6829397
[No Abstract] [Full Text] [Related]
8. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
[TBL] [Abstract][Full Text] [Related]
10. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
Snider DE; Graczyk J; Bek E; Rogowski J
Am Rev Respir Dis; 1984 Dec; 130(6):1091-4. PubMed ID: 6508006
[TBL] [Abstract][Full Text] [Related]
11. Rifampicin hepatitis. A clinical and histological study.
Scheuer PJ; Summerfield JA; Lal S; Sherlock S
Lancet; 1974 Mar; 1(7855):421-5. PubMed ID: 4131429
[No Abstract] [Full Text] [Related]
12. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
[TBL] [Abstract][Full Text] [Related]
13. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
[TBL] [Abstract][Full Text] [Related]
14. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
Ige OM; Bakare NA; Onadeko BO
Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469
[TBL] [Abstract][Full Text] [Related]
15. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.
Snider DE; Rogowski J; Zierski M; Bek E; Long MW
Am Rev Respir Dis; 1982 Feb; 125(2):265-7. PubMed ID: 7065534
[TBL] [Abstract][Full Text] [Related]
16. [Rifampicin in the treatment of active pulmonary tuberculosis. Controlled trial of isoniazid-rifampicin-thiocarlide versus isoniazid-streptomycin-thiocarlide in untreated tuberculosis. Treatment of relapses with the combination rifampicin-ethambutol-thiocarlide].
Chioléro R
Schweiz Med Wochenschr; 1974 Mar; 104(10):356-64. PubMed ID: 4206521
[No Abstract] [Full Text] [Related]
17. Treatment of tuberculosis in patients with pre-existing liver disease or following hepatotoxic drug reactions.
Robson SC; Pillans P; Willcox PA
S Afr Med J; 1993 Jun; 83(6):432-4. PubMed ID: 8211464
[No Abstract] [Full Text] [Related]
18. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
19. [Short-term treatment of tuberculosis with and without pyrazinamide in the second phase (TA-80)].
Farga V; Valenzuela P; Yañez A; Valenzuela MT; Scheel G; Mendoza F; Torres E; Icekson I; Grinspun M; Fernández M
Rev Med Chil; 1983 Jul; 111(7):750-4. PubMed ID: 6680460
[No Abstract] [Full Text] [Related]
20. [Renal tuberculosis treated with rifampicin, isoniazid and ofloxacin].
Alberte A; Martínez-Sagarra JM; Estébanez MJ; Pascual PP
Enferm Infecc Microbiol Clin; 1992 Apr; 10(4):216-9. PubMed ID: 1606225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
